Intensity-modulated radiation therapy with hypoxic sensitizer AK-2123 (sanazole) for glioblastoma multiforme using simultaneous integrated boost technique.

Abstract

BACKGROUND:

Glioblastoma has a very poor prognosis even after incorporation into therapy of the newly-developed drug, temozolomide.

CASE REPORT:

We present a case of 62-year-old woman with glioblastoma multiforme treated with tomotherapy intensity-modulated radiation therapy using simultaneous integrated boost technique (SIB-IMRT) along with a daily oral dose of a hypoxic radiation sensitizer, sanazole (AK-2123). SIB-IMRT was administered at a dose of 60 Gy in 20 fractions for high-risk planning target volume (PTV) and at 40 Gy for low-risk PTV. The patient received an oral administration of sanazole (1.0 g/day) for 10 days, 2 h before radiotherapy. She achieved a complete response without any adverse events, and remained disease-free for 3.5 years. Our study demonstrates that the higher single-dose radiotherapy combined with a hypoxic radiation sensitizer has the potential to enhance the efficacy of radiotherapy.

• Authors: Hideya Yamazaki, Satoaki Nakamura, Takuya Nishimura, Haruumi Okabe, Norihiro Aibe, Ken Yoshida, Tsutomu Kagiya
• Journal: Anticancer research (Anticancer Res) Vol. 33 Issue 4 Pg. 1685-8 (Apr 2013) ISSN: 1791-7530 [Electronic] Greece
• PMID: 23564816 (Publication Type: Case Reports, Journal Article)

Chemical References

• Radiation-Sensitizing Agents
• Triazoles
• AK 2123

Topics

• Brain Neoplasms (drug therapy, radiotherapy)
• Chemoradiotherapy
• Female
• Glioblastoma (drug therapy, radiotherapy)
• Humans
• Hypoxia
• Middle Aged
• Prognosis
• Radiation-Sensitizing Agents (therapeutic use)
• Radiotherapy Planning, Computer-Assisted
• Radiotherapy, Intensity-Modulated
• Triazoles (therapeutic use)